Our News

See our press releases, presentations, and corporate information.

ournews-mobile (1)

Press Room

Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024 >

May 9, 2024

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults >

May 8, 2024

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024 >

May 7, 2024

Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference >

May 7, 2024

Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring >

May 6, 2024

Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024 >

May 3, 2024

Neurocrine Biosciences Reports First Quarter 2024 Financial Results >

May 1, 2024

Resources

Resources

Our

Leadership

Investor

Information